Ebrahim NAA, Elfandy H, Arafat AMA, Darwish AD, Eltohamy MI. Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms. World J Clin Oncol 2026; 17(1): 111426 [DOI: 10.5306/wjco.v17.i1.111426]
Corresponding Author of This Article
Noura A A Ebrahim, MD, MSc, PhD, Assistant Professor, Department of Oncologic Pathology, National Cancer Institute, Cairo University, 1st Kasr Alainy Street, Cairo 11796, Al Qāhirah, Egypt. npathologist@gmail.com
Research Domain of This Article
Pathology
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Jan 24, 2026; 17(1): 111426 Published online Jan 24, 2026. doi: 10.5306/wjco.v17.i1.111426
Evaluating murine double minute 2 status as a stratification tool for risk-adapted management in plasma cell neoplasms
Noura A A Ebrahim, Habiba Elfandy, Aya Mohamed Adel Arafat, Amira Diyaa Darwish, Mahitab Ibrahim Eltohamy
Noura A A Ebrahim, Habiba Elfandy, Mahitab Ibrahim Eltohamy, Department of Oncologic Pathology, National Cancer Institute, Cairo University, Cairo 11796, Al Qāhirah, Egypt
Aya Mohamed Adel Arafat, Department of Clinical and Chemical Pathology, Kasr Al-Aini Faculty of Medicine, Cairo University, Cairo 11562, Egypt
Amira Diyaa Darwish, Department of Medical Oncology, National Cancer Institute, Cairo University, Cairo 11796, Al Qāhirah, Egypt
Co-first authors: Noura A A Ebrahim and Habiba Elfandy.
Author contributions: Ebrahim NAA and Elfandy H contributed equally to this manuscript and are co-first authors. All authors made equal and substantial contributions to the conception, design, data analysis, and writing of the manuscript. Each author has reviewed and approved the final version and agrees to be accountable for all aspects of the work.
Institutional review board statement: This investigation was carried out following the ethical principles stated in the Declaration of Helsinki. Ethical approval was granted by the Institutional Review Board of the National Cancer Institute, Cairo University, Approval No. PA2505-506-104-199.
Informed consent statement: As the study was retrospective and utilized anonymized data, the IRB granted a waiver for the requirement of informed consent.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement:
The datasets generated or analyzed during the current study are available from the corresponding author upon reasonable request.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Noura A A Ebrahim, MD, MSc, PhD, Assistant Professor, Department of Oncologic Pathology, National Cancer Institute, Cairo University, 1st Kasr Alainy Street, Cairo 11796, Al Qāhirah, Egypt. npathologist@gmail.com
Received: July 7, 2025 Revised: July 29, 2025 Accepted: December 11, 2025 Published online: January 24, 2026 Processing time: 205 Days and 10 Hours
Core Tip
Core Tip: This research explores the prognostic significance of murine double minute 2 (MDM2) expression in plasma cell neoplasms, with particular attention to plasmacytomas. The findings reveal a distinct subset of patients with MDM2 positivity who demonstrate poorer early treatment responses and markedly shorter relapse-free survival intervals. Incorporating MDM2 expression into contemporary prognostic frameworks could enhance individualized treatment planning for those with multiple myeloma. Overall, the evidence indicates that MDM2 functions as both a marker of aggressive tumor biology and a promising indicator for early-stage risk stratification, supporting more vigilant follow-up and personalized therapeutic intervention to reduce relapse likelihood.
